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Abstract
Background—Inflammasome-mediated neuroinflammation may cause secondary injury 
following traumatic brain injury (TBI) in children. The pattern recognition receptors NLRP1 and 
NLRP3 are essential components of their respective inflammasome complexes. We sought to 
investigate whether NLRP1 and/or NLRP3 abundance is altered in children with severe TBI.
Methods—Cerebrospinal fluid (CSF) from children (n=34) with severe TBI (Glasgow coma 
scale score [GCS] ≤8) who had externalized ventricular drains placed for routine care was 
evaluated for NLRP1 and NLRP3 at 0–24h, 25–48h, 49–72h, and >72h post-TBI and was 
compared to infection-free controls that underwent lumbar puncture to rule out CNS infection 
(n=8). Patient age, sex, initial GCS, mechanism of injury, treatment with therapeutic hypothermia, 
and 6 month Glasgow outcome score (GOS) were collected.
Results—CSF NLRP1 was undetectable in controls and detected in 2 TBI patients and at only 
<24h post-TBI. CSF NLRP3 levels were increased in TBI patients compared with controls at all 
time points, p<0.001. TBI patients ≤ 4 years of age had higher peak NLRP3 levels vs. patients > 4 
(15.50 [3.65–25.71] vs. 3.04 [1.52–8.87] ng/mL, respectively; p=0.048). Controlling for initial 
GCS in multivariate analysis, peak NLRP3 > 6.63ng/mL was independently associated with poor 
outcome at 6 months.
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Conclusions—In the first report of NLRP1 and NLRP3 in childhood neurotrauma we found that 
CSF NLRP3 is elevated in children with severe TBI and independently associated with younger 
age and poor outcome. Future studies correlating NLRP3 with other markers of inflammation and 
response to therapy are warranted.
Keywords
NLRP3; NLRP1; Inflammasome; Traumatic brain injury; Biomarker; Neuroinflammation; 
Secondary Brain Injury; Pediatric
INTRODUCTION
Traumatic brain injury (TBI) accounts for over 60,000 hospitalizations in children per year 
in the U.S. alone and is a major cause of trauma-related morbidity and mortality1,2. The 
neuroinflammatory response to TBI, activated by the release of host-derived proteins termed 
danger associated molecular patterns (DAMPs), may lead to delayed neuronal death and 
impact recovery. Several studies indicate a critical role for the inflammasome complex in 
initiating the immune response to DAMPs after brain trauma3,4. Multiple inflammasome 
complexes have been described within the central nervous system (CNS) including NACHT 
domain-, Leucine rich repeat-, and PYD-containing Protein 1 (NLRP1) and NLRP3. The 
inflammasome complex amplifies cleavage of pro-caspase-1 to caspase-1, which then 
cleaves pro-interleukin (IL)-1β and pro-IL-18 to the active cytokines 5–9. Caspase-1 and 
IL-1β are rapidly activated after TBI and protein levels remain elevated through 3 days post-
injury 10. Adults with severe TBI were found to have detectable cerebrospinal fluid (CSF) 
levels of NLRP1 and caspase-1 which correlated with functional outcome at 5 months post-
TBI 5. In children with severe TBI, caspase-1 levels are increased in CSF after TBI, 
particularly in patients ≤ 4 years old 11.
NLRP1 inflammasome complex formation and lesion volume in a TBI model are reduced by 
antibody to the inflammasome adaptor protein apoptosis-associated speck-like protein 
containing a CARD (ASC) 7. In another TBI model, NLRP3 and inflammasome complexes 
were found to be increased in the pericontusional cortex following injury 9.
To date, there have been no studies of the NLRP1 or NLRP3 inflammasome proteins after 
childhood trauma. We hypothesized that the NLRP1 and NLRP3 would be increased after 
severe TBI in children and detectable in CSF compared with uninjured control subjects. and 
that NLRP1 and NLRP3 would be associated with clinical variables and outcome (Glasgow 
Outcome Scale [GOS] score). We believe that these studies could provide evidence for this 
innate immune system mechanism within such patients, justifying evaluation of therapies 
targeting inflammasome-mediated neuroinflammation.
MATERIALS AND METHODS
Patients
All of the study procedures outlined below, including the collection of CSF from children 
with severe TBI, data collection from the medical records and interventions as part of the 
parent studies, were approved by the Institutional Review Board of the University of 
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Pittsburgh. Children (age ≤ 18 years at the time of injury) with severe TBI (Glasgow Coma 
Scale score (GCS) ≤ 8) who had an externalized ventricular drain (EVD) placed as part of 
their standard care were eligible for inclusion in this study (n = 34). CSF samples were 
collected at four time points after injury: <24h, 25–48h, 49–72h, and >72h. Once collected, 
CSF was centrifuged to remove cellular debris and stored at −80°C for batch analysis. CSF 
from children undergoing lumbar puncture to rule out CNS infection, but ultimately shown 
to be infection-free, was used as control (n = 8).
Management of children with severe TBI at our institution has been previously described 
and is in accordance with the most recent evidence-based guidelines12. A subset of children 
included in this study were enrolled in a randomized, controlled trial of early therapeutic 
hypothermia (32–33°C for 48h) after severe TBI (NCT00222742)13. The following variables 
were recorded: age at the time of injury, patient sex, race, GCS, mechanism of injury, 
diagnosis of abusive head trauma by the hospital’s Child Advocacy Center, use of 
therapeutic hypothermia, and GOS at 6 months after injury.
Enzyme-Linked Immunosorbent Assay (ELISA)
Commercially available ELISA kits for NLRP1 and NLRP3 (MyBioSource, San Diego, CA) 
with detection ranges of 18.75 – 1200 pg/mL and 0.156 – 10 ng/mL, respectively, were used 
for this analysis. All procedures were performed in accordance with the manufacturer’s 
instructions. Specifically, standards and CSF samples (100 μL) were loaded into wells and 
incubated for 2 hours at 37°C. The primary biotin-antibody was added to each well and 
incubated at 37°C for 1 hour. Following a buffer wash, the secondary antibody and detector 
horseradish peroxidase (HRP)-avidin was added to all wells for a 1-hour incubation at 37°C. 
The chromogenic substrate - 3,3′,5,5′-Tetramethylbenzidine (TMB) - was then applied, the 
plate was covered in foil, and then incubated at 37 degrees for 30 min. Lastly, the stop 
solution was added and the optical density was measured using a microplate reader set to 
450 nm with a correction wavelength of 540 nm. A standard curve was created and the 
concentrations of NLRP1 and NLRP3 from individual samples were determined.
Statistical Analysis
Demographic information among cases versus controls was examined using the Fisher exact 
test and student’s t-test for categorical and continuous variables, respectively. Trends in 
NLRP1 and NLRP3 across the four time points were analyzed using repeated measures 
ANOVA. Age and GOS variables were a priori dichotomized to facilitate analysis with 
respect to NLRP3 level. Further analysis between NLRP3 and demographic data was 
completed using the Mann-Whitney U Test. A receiver operating characteristic (ROC) curve 
was generated for peak NLRP3 level with relationship to outcome. Youden’s J statistic was 
calculated for optimal NLRP3 cutoff to predict poor outcome and this was used in univariate 
and multivariate logistic regression analysis. Multivariate analysis was performed to 
determine associations between peak NLRP3 and 6 month GOS adjusting for GCS and 
demographic variables with p<0.1 in univariate analysis. All NLRP3 values are provided as 
median [interquartile range] or mean [±SEM] with two-sided p < 0.05 considered 
statistically significant. Calculations were performed with GraphPad Prism (GraphPad 
Software, Inc., La Jolla, CA) and SPSS version 23 (IBM Corp, Armonk, NY).
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RESULTS
Thirty-four children who suffered severe TBI were included in the study, contributing a total 
of 122 CSF samples (Table 1). Median GCS was 7 (range: 3–14). Motor vehicle accident 
(MVA) was the most common mechanism of injury (29.4%), followed by pedestrian 
accidents (11.8%), abusive head trauma (AHT 17.6%), falls (14.7%), and other mechanisms 
(26.5%). Sixteen patients (47%) were part of the Cool Kids trial. Of these, 7 (43.75%) were 
randomized to therapeutic hypothermia. All other patients received standard care. Most of 
the case population (91.2%) identified as Caucasian. These cases were compared to 8 
controls which had similar mean age (7.68 years [±0.88] vs 10.69 years [±2.18] respectively, 
p=0.160) and sex (67.6% vs 75.0% male, p=1.00) across groups.
NLRP1 was detectable in a pilot study of 2 out of 18 patients (11%) with severe TBI at 0–
24h and in each case returned to undetectable levels by 24–48h. Additionally, none of the 8 
control patients had detectable levels of NLRP1 in their CSF. Given the lack of NLRP1 
elevation after pediatric trauma in the initial samples, additional analysis of NLRP1 was not 
performed.
Twenty-six patients had CSF measured at all four time frames and 8 patients had CSF 
measured at 1 – 3 time frames. NLRP3 was detectable in all 122 CSF samples tested from 
cases (Table 2) and in all 8 controls. Among the 26 cases with four NLRP3 measurements, 
the concentration of NLRP3 was significantly higher than controls at all four time frames 
(0–24h: 5.75 ng/mL [1.56 – 21.55], 25–48h: 1.87 ng/mL [0.82 – 4.86], 49–72h: 2.43 ng/mL 
[0.75 – 6.57], >72h: 4.12 ng/mL [1.71 – 9.74], controls: 0.33 ng/mL [0.26 – 0.47]; p < 0.001 
at all time points) (Figure 1). We determined the minimum NLRP3 value for each patient 
across the 4 time frames and compared those values to controls and found the group median 
was 1.15 ng/mL [0.70 – 2.91] vs. 0.33 ng/mL [0.26 – 0.47] in cases vs. controls, 
respectively, p<0.001.
NLRP3 levels showed a significant change over time. The most common temporal pattern 
was a peak within the first 24 hours after TBI, decreased between 25–48, then increased at 
samples taken from 48–72h and > 72h. Repeated measures ANOVA revealed this to be a 
significant quadratic trend, p<0.001, rather than a linear relationship.
Younger patients (≤ 4 years) had a higher peak NLRP3 level (group median 15.50 ng/mL 
[3.65–25.71]) compared with older patients (age > 4 years) (group median 3.04 ng/mL 
[1.52–8.87], p=0.048) (Figure 2).
The 6 month GOS was dichotomized into favorable outcome (GOS 1–2) vs unfavorable 
outcome (GOS 3–5). A ROC curve was generated for peak NLRP3 concentration prediction 
of 6 month GOS with an AUC of 0.69. The optimal NLRP3 cutoff (defined as that which 
maximizes the sum of sensitivity and specificity, or equivalently, Youden’s J statistic) was 
6.63 ng/mL, which gave a sensitivity of 0.67 and specificity of 0.86 (Figure 3). TBI patients 
with an NLRP3 level > 6.63 ng/mL at any time point were at higher risk for poor outcome 
(RR 7.6 95%CI: [1.40–45.62], p=0.013). Univariate regression analysis of age, gender, GCS, 
and mechanism of injury did not yield significant associations of these variables to CSF 
NLRP3. CSF NLRP3 level > 6.63 ng/mL was independently associated with GOS when 
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controlling for initial GCS to adjust for injury severity (Table 3; OR 10.34, 95%CI: [1.04–
102.78], p=0.046).
DISCUSSION
We found the CSF concentration of NLRP3 is elevated in children with severe TBI. In 
addition, we observed age-related differences, with higher peak NLRP3 level measured in 
children ≤ 4y. Lastly, a peak NLRP3 > 6.63ng/mL was independently associated with poor 
outcome when controlling for injury severity. NLRP1, in contrast, was detected in only 11% 
of children with severe TBI. In these two patients, NLRP1 was found elevated in the CSF at 
≤ 24h and was undetectable on subsequent measurements. This is the largest study to date in 
patients with severe TBI that has measured NLRP1 or NLRP3 and the only study of these 
inflammasome components in children.
NLRP1 and NLRP3 are members of the NOD-like receptor (NLR) protein family of 
cytosolic pattern recognition receptors (PRR), activated by various infectious triggers or in 
response to sterile danger signals such as uric acid, ATP, or oxidative stress 4,6,14. Activation 
of NLRP1 or NLRP3 results in assembly of the inflammasome, a multiprotein complex most 
often composed of a PRR such as NLRP1 or NLRP3, the adaptor protein ASC, and 
caspase-1. The inflammasome amplifies activation of caspase-1, thereby increasing 
subsequent processing of pro-IL-1β and pro-IL-18 into active forms, and may result in the 
pro-inflammatory pathway of regulated necrosis called pyroptosis 4,15. The NLRP1 
inflammasome, the first inflammasome described, is classically activated by the Bacillus 
anthracis toxin 8,16. The NLRP3 inflammasome has been shown to respond to a wide variety 
of triggers, including pathogen associated molecular patterns (PAMPs) and DAMPs 6,8,17 
that may be released in response to TBI or subsequent infection.
Studies in experimental brain injury models and in adults with moderate to severe TBI have 
suggested a role for the NLRP1 and NLRP3 inflammasomes in mediating post-traumatic 
neuroinflammation. Adamczak et al. 5 and de Rivero Vaccari et al. 7 performed the only 
previous studies to measure NLRP1 in patients with TBI, both of which were performed in 
adults with moderate to severe injury. Increased levels of ASC, caspase-1, and NLRP1 were 
detected and associated with unfavorable outcome at 5 months. NLRP1 and NLRP3 are 
intracellular PRRs, however de Rivero Vaccari et al. 18 showed evidence of NLRP1 in 
exosomes isolated from the CSF of patients with TBI. In contrast to the evidence supporting 
the role of NLRP1 in patients with TBI, NLRP3 expression has previously only been shown 
in in vivo TBI models. In the study by Liu et al. 9 increased expression of NLRP3, ASC, and 
caspase-1 mRNA was detected by 6 hours after fluid percussion injury and increased protein 
concentration of NLRP3 and cleaved Caspase-1 were measured in brain homogenates by 24 
hours. Immunoprecipitation studies showed protein-protein interactions between NLRP3 
and ASC suggesting formation of the inflammasome complex. It is possible that some or all 
of the NLRP3 we detected in CSF of children with severe TBI was present in extracellular 
vesicles (EVs) including exosomes, and also possible that NLRP1 was infrequently detected 
in our study because it was confined to EVs. This could allow for cell-cell communication 
and activation, or conversely could be used to limit NLRP1 or NLRP3 activation in cells.
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Of significant interest in our study is the association of age ≤ 4 y with higher peak NLRP3 
concentration. Although epidemiologic studies of TBI have generally shown that pediatric 
patients have better outcomes than adults with similar severity of injury, the youngest 
children tend to have worse outcomes than other pediatric patients19. Children ≤ 4 y may be 
at particular risk for poor outcome due to a higher incidence of abusive head trauma, delayed 
presentation, hypoxic injury, or seizures 20–22. Several clinical investigations have 
demonstrated a more robust neuroinflammatory response to head trauma in young children 
and this may also impact outcomes. For example, Newell et al. 23 examined CSF levels of 
ferritin, a marker of macrophage activation, in pediatric patients with severe TBI and found 
an association between high ferritin and age ≤ 4 y. Similarly, Satchell et al. 11 found an 
increased concentration of caspase-1 in the CSF of children ≤ 4 years after severe TBI. The 
latter study is of particular relevance, as caspase-1 activation is highly amplified by the 
inflammasome complex and therefore may be due to an increase in NLRP3 production and 
inflammasome activation.
We observed that peak CSF NLRP3 > 6.63 ng/mL significantly increased the risk of poor 
outcome, even when controlling for TBI severity as measured by GCS. Previous studies of 
the cytokine IL-1β, which is activated by the inflammasome and increases after TBI in 
adults and children 24–28, have shown mixed results as a predictor of functional outcome. 
Antagonism of IL-1β signaling has been supported in pre-clinical TBI models29–31 and a 
randomized controlled phase II trial of IL-1 receptor antagonist in adults with severe TBI 
showed the drug entered the CNS, was not associated with adverse events, and altered the 
neuroinflammatory response. Direct inhibitors of inflammasome-mediated inflammation 
have been developed and may be more effective in regulating pro-inflammatory pathways, as 
they will also be expected to limit IL-18 activation, secretion, and pyroptotic cell death32–35. 
Examples of therapies shown to inhibit NLRP3 include ketogenic diet 36, the small molecule 
MCC95037{Coll, 2015 #4;Coll, 2015 #4}, minocycline, and glyburide38 that are being 
tested in TBI and other CNS injuries including stroke, subarachnoid hemorrhage, and spinal 
cord injury. Combined with predictive information, these potential therapies could be useful 
outside the initial resuscitation and 24 hours of hospitalization, allowing physicians to 
deliver targeted therapy for the patients at highest risk of poor outcome.
In this study, NLRP3 was measured at 4 time points to reveal temporal trends. NLRP3 levels 
changed significantly over time, and fit a quadratic regression curve indicating that NLRP3 
levels were high on post-injury day 1, lower on day 2, and increased again on post-injury 
day 3 or 4. Although the initial increase in NLRP3 may be due to traumatic lysis or necrotic 
cell death, the late rise in NLRP3 levels seen after 48 hours may represent cellular stress 
from elevated ICP, infection, or other triggers leading to inflammasome activation.
Limitations in this investigation include the fact that pediatric TBI is a heterogeneous 
disease and that we were unable to evaluate the effects of various injury patterns and 
mechanisms of injury. Also we have only included those patients with severe injury defined 
as GCS ≤ 8 who had EVD placement and treatment according to a predefined protocol. We 
did not measure other inflammatory or cell death biomarkers such as IL-1 or IL-18 that have 
been used as markers of inflammasome activation.
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CONCLUSIONS
In conclusion, this investigation demonstrates that there is a significant and sustained 
increase in CSF NLRP3 concentrations in pediatric patients with severe TBI compared to 
controls. This increase is most pronounced in younger patients and a peak NLRP3 level > 
6.63 ng/mL is associated with poor outcome. While these data are consistent with 
inflammasome activation in the largest number of TBI patients to-date, larger studies using 
targeted interventions are needed to confirm a role for inflammasome-mediated 
neuroinflammation after TBI.
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Figure 1. CSF concentration of NLRP3 over time after traumatic brain injury in children
CSF NLRP3 concentration was determined at all four time points in 26 cases, and at a single 
time point in 8 controls. The CSF levels of NLRP3 in children with severe TBI were 
significantly increased at all four time points vs. controls. The temporal trend fit a quadratic 
regression line (p<0.001). (*p < 0.001 vs. control).
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Figure 2. Maximum NLRP3 level by age
Younger children (age 0–4 years) had a higher peak NLRP3 level of 15.50 ng/mL [3.65–
25.71] compared to older patients (age ≥ 5 years) at 3.04 ng/mL [1.52–8.87], p=0.048.
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Figure 3. ROC curve of peak NLRP3 level for prediction of 6 month dichotomized GOS
ROC curves were generated for peak NLRP3 level. The AUC was 0.72, indicating moderate 
predictive value. Youden’s J statistic determined the optimal NLRP3 cutoff was 6.63 ng/mL, 
which gave a sensitivity of 0.71 and specificity of 0.77.
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Table 1
Demographic Data for Children with Severe Traumatic Brain Injury and Controls
TBI Control
N
 All 34 8
 ≤ 4y 12 (35.3) 2 (25)
 5–18y 22 (64.7) 6 (75)
Age, years 7.68 ± 2.18 10.69 ± 0.89
Male 23 (67.6) 6 (75)
Race
 Caucasian 31 (91.2)
 African American 1 (2.9)
 Other 2 (5.9)
GCS 7 [3–14]
Mechanism of injury
 MVA 10 (29.4)
 Pedestrian vs Vehicle 4 (11.8)
 Abusive Head Trauma 6 (17.6)
 Fall 5 (14.7)
 Other 9 (26.5)
GOS
 5 (good) 16 (47.1)
 4 (moderate disability) 11 (32.4)
 3 (severe disability) 3 (8.8)
 2 (vegetative) 0 (0)
 1 (death) 4 (11.8)
Data presented as mean ± SE, n (%), median[range] as appropriate
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Table 2
Mean and Peak NLRP3 levels by Demographics in Children with Severe TBI
Mean NLRP3 Level Peak NLRP3 Level
All Children with Severe TBI 2.65 [1.73–11.37] 4.76 [1.70–18.50]
Age
 ≤ 4 years 9.00 [1.73–11.37] 15.50 [3.65–25.71]
 > 4 years 2.12 [1.06–5.27] 3.04 [1.52–8.87]
Sex
 Male 2.58 [1.35–11.65] 6.10 [1.53–21.16]
 Female 3.64 [1.17–5.26] 4.11 [2.20–17.59]
Mechanism of Injury
 MVA 3.96 [1.89–14.45] 13.63 [2.96–27.75]
 Pedestrian vs. Vehicle 1.36 [0.91–7.08] 2.49 [1.01–14.06]
 Abusive Head Trauma 1.86 [1.02–9.09] 6.26 [1.50–17.99]
 Fall 4.02 [0.99–10.10] 5.40 [1.87–19.78]
 Other 2.71 [1.06–4.98] 2.94 [1.40–9.16]
GOS
 Favorable Outcome (4–5) 1.91 [1.09–8.77] 3.49 [1.53–17.59]
 Unfavorable Outcome (1–3) 6.09 [3.84–9.37] 8.59 [7.16–26.36]
Data presented as median [IQR]
MVA, motor vehicle accident; GOS, Glasgow Outcome Scale
Neurocrit Care. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wallisch et al. Page 15
Table 3
Associations Between Increased Cerebrospinal Fluid NLRP3a and Clinical Variables
Univariate Multivariate
p OR [95% CI] p
Age 0.283
Sex 0.400
GCS 0.185 1.17 [0.81–1.68] 0.401
Mechanism 0.335
GOS at 6 months 0.031 10.34 [1.04 – 102.78] 0.046
a
Increased NLRP3 defined as > 6.63 ng/mL
CI, confidence interval; OR, odds ratio; GCS, Glasgow Coma Sale score; GOS, Glasgow Outcome Scale score
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